== Hyperglycemia triggers filopodial-like projections in SMCs
== Hyperglycemia triggers filopodial-like projections in SMCs. For each condition, the number of projections in 30 40 cells in lower power fields was counted and scored as <10, 10 100, or >100. and the integrin modulator Rap1 under conditions of hyperglycemia. These results suggest that there are differences in SMC responses to vascular injury depending on the presence or absence of hyperglycemia and that SMC response under hyperglycemic conditions is largely mediated through 3 Umibecestat (CNP520) integrin signaling Keywords:intima, easy muscle cells, hyperglycemia, restenosis, proliferation == 1. Introduction == Vascular complications, including premature and accelerated atherosclerosis of the coronary, renal, cerebral, and peripheral arteries, are major causes of morbidity and mortality in diabetic patients (Beckman et al., 2002;Ceriello, 2004). Diabetic patients also display higher rates of formation of neointimal hyperplasia and Umibecestat (CNP520) its clinical correlate, restenosis, after percutaneous vascular interventions (Jimenez-Quevedo and Sabate, 2005;Karha and Bhatt, 2004). In the Diabetes Control and Complications Trial (DCCT), 1229 individuals (85%) with Type 1 diabetes had increased carotid intimamedia thickness as compared with age- and sex-matched controls (Nathan et al., 2003), and comparable findings have been observed in other clinical studies (Giannattasio et al., 2001;Yamasaki et al., 1994). Patients with type 2 diabetes also have PPP3CC greater carotid intimamedia thickness when compared to their nondiabetic counterparts (Folsom et al., 1994;Wagenknecht et al., 1998). Similarly accelerated intimal hyperplasia has been observed in both type 1 and type 2 diabetic animal models (Jonas et al., 2005;Salzberg et al., 2006;Sasaki et al., 2008). In response to vascular injury, such as that from atherosclerosis or vascular instrumentation, easy muscle cells (SMC) residing in the vessel wall are stimulated to proliferate and migrate, resulting in the development of neointimal hyperplasia. Various changes in the vascular environment, including alterations in the extracellular matrix and in the basement membrane, promote the conversion of normally quiescent, non-motile SMCs into cells that rapidly grow and migrate (Hedin et al., 1999;Raines, 2000). The conversation of SMCs with their extracellular matrix is usually governed, in large part, by members of the integrin family of adhesion receptors (Moiseeva, 2001). Integrin V3, in particular, may contribute to these events (Moiseeva, 2001;Stouffer et al., 1998;Stouffer and Smyth, 2003). The molecular mechanisms responsible for accelerated atherosclerosis and restenosis in diabetes are incompletely comprehended, although several factors have been proposed to play a role. Among these is usually activation of protein kinase C (Yan et al., 2006), which may occur in diabetes as a consequence of de novo synthesis of diacylglycerol (DAG), increases in reactive oxygen species, and/or production of cytokines. In the setting of hyperglycemia, de novo synthesis of DAG may be stimulated by the accumulation of the glycolytic intermediate glycerol-3-phosphate or by flux through the polyol pathway, which produces dihydroxyacetone phosphate that is converted sequentially to lysophosphatidic acid, phosphatidic acid, and finally DAG. In the SMC, DAG-responsive conventional PKC isoforms, such as PKC and , are Umibecestat (CNP520) activated by hyperglycemia (Nakamura et al., 2001). Among the PKC isoforms, PKC II has been implicated as a key mediator of hyperglycemia-induced Raf/MEK/ERK signaling, and hyperglycemia-induced potentiation of SMC proliferation and migration (Campbell et al., 2004). However, the molecular mechanisms that regulate PKC in the setting of hyperglycemia are not known. Furthermore, the coupling of PKC activation to integrin-sensed changes in the ECM, such as those that occur following vascular injury, are not well comprehended. Some (Lincoff et al., 1999;Marso et al., 1999), but not all clinical studies (Lincoff, 2003), have suggested that this combination of the integrin 3 antagonist abciximab, with stent implantation, results in a complementary decrease in adverse clinical events in diabetic patients, but not in nondiabetic patients. This includes reductions in the need for target vessel revascularization, which is a clinical marker for restenosis. These observations suggest that integrin 3 may play an important role in restenosis in the context of diabetes. Activation of the hexosamine pathway by glucose catabolism in vascular SMCs upregulates.